The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.

Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...

"Our approach achieved remarkably high levels of gene correction," said Dr. György. "We observed average editing rates of 75% ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J., Jan.

Updates on commercial insights and readiness plans for sozinibercept in wet AMDOpthea management to present in New York City on Tuesday, January ...

From redness to gradual loss of vision to constant irritation, here are the early warning signs of eye diseases that should not be taken lightly.

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

An announcement from Opthea Limited ( ($AU:OPT) ) is now available. Opthea Limited announced the publication of its Phase 1b ...